Loading...
Please wait, while we are loading the content...
Similar Documents
Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
| Content Provider | Semantic Scholar |
|---|---|
| Author | Sim, Ki Choon Park, Beom Jin Han, Na Yeon Sung, Deuk Jae Cho, Sung Bum Ha, Hyun Kwon Kim, Hyoung R. |
| Copyright Year | 2014 |
| Abstract | Gastrointestinal stromal tumors (GISTs) are the most common and comprise the majority of mesenchymal tumors of the gastrointestinal tract; unlike other tumors, they are considered potentially malignant (1). Surgery is the principal initial treatment for patients with an operable GIST, but curative therapy is difficult in more than half of patients with a malignant GIST due to the dispersed nature of the tumor, and high postoperative recurrence and metastasis rates are observed (40–90% of all surgically treated cases) (2-4). Malignant GISTs often fail to respond to treatment with conventional cytotoxic agents such as doxorubicin-based therapy and radiotherapy, and when there is a response, it is often not sustained (5, 6). Imatinib mesylate (imatinib; formerly STI571), is a molecularly targeted drug that selectively inhibits constitutive activity of the KIT receptor tyrosine kinase in GIST cells. Imatinib reduces tumor size and arrests disease progression in > 80% of patients with advanced GIST (7-9). Adjuvant imatinib treatment also improves recurrence-free survival in patients with localized primary GIST (10). Previous studies have indicated a dramatic change in tumor Original Article |
| Starting Page | 239 |
| Ending Page | 248 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| DOI | 10.3348/jksr.2014.71.5.239 |
| Volume Number | 71 |
| Alternate Webpage(s) | https://jksronline.org/Synapse/Data/PDFData/2016JKSR/jksr-71-239.pdf |
| Alternate Webpage(s) | https://doi.org/10.3348/jksr.2014.71.5.239 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
